Vaccination of puppies born to immune dams with a canine adenovirus-based vaccine protects against a canine distemper virus challenge

Vaccine

Volumn 20, Issue 29-30, 2002, Pages 3485-3497

  Fischer, Laurent ^a   Tronel, Jean Philippe ^a   Pardo David, Camilla ^a   Tanner, Patrick ^a   Colombet, Guy ^a   Minke, Jules ^a   Audonnet, Jean Christophe ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

CDV; DNA vaccine; Dogs

Indexed keywords

VIRUS ANTIGEN; VIRUS FUSION PROTEIN; VIRUS HEMAGGLUTININ; VIRUS VACCINE; VIRUS VECTOR;

ADENOVIRUS; ADENOVIRUS 2; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANINE DISTEMPER MORBILLIVIRUS; CARNIVORE; CONTROLLED STUDY; DOG; DOG DISEASE; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROTEIN ENGINEERING; VACCINATION; VIRUS CHARACTERIZATION; VIRUS RECOMBINANT; VIRUS REPLICATION;

ADENOVIRUSES, CANINE; ANIMALS; ANTIBODIES, VIRAL; CHROMOSOME MAPPING; DISTEMPER VIRUS, CANINE; DOGS; HEMAGGLUTINATION, VIRAL; VACCINATION; VACCINES, SYNTHETIC; VIRAL FUSION PROTEINS; VIRAL VACCINES;

EID: 0037019923     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00344-4     Document Type: Article

References (36)

1. Barrett T. Morbillivirus infections, with special emphasis on morbilliviruses of carnivores. Vet. Microbiol. 69:1999;3-13.
2. Appel M.J., Shek W.R., Shesberadaran H., Norrby E. Measles virus and inactivated canine distemper virus induce incomplete immunity to canine distemper. Arch. Virol. 82:1984;73-82.
3. Roth J.A. Mechanistic bases for adverse vaccine reactions and vaccine failure. Adv. Vet. Med. 41:1999;681-700.
4. Klonjkowski B, Denesvre C, Eloit M. Adenoviral vectors for vaccines. In: Seth P, editor. Adenovirus: basic biology to gene therapy. Austin: Landes; 1999. p. 163-73.
5. Gallichan W.S., Johnson D.C., Graham F.L., Rosenthal K.L. Mucosal immunization with a recombinant adenovirus vector induces local and systemic immunity and protection from herpes simplex virus. Adv. Exp. Med. Biol. 371:1995;581-585.
6. Rosenthal KL, Copeland KFT, Gallichan WS. Recombinant adenovirus as vectors for mucosal immunity. In: Kiyono H, Ogra PL, McGhee JR, editors. Mucosal vaccines. San Diego: Academic Press; 1996. p. 147-58.
7. Papp Z., Middeltown D.M., Mittal S.K., Babiuk L.A., Baca-Estrada M.E. Mucosal immunization with recombinant adenoviruses: induction of immunity and protection of cotton rats against respiratory bovine herpesvirus type 1 infection. J. Gen. Virol. 78:1997;2933-2943.
8. Papp Z., Babiuk L.A., Baca-Estrada M.E. The effect of pre-existing adenovirus-specific immunity on immune responses induced by recombinant adenovirus expressing glycoprotein D of bovine herpesvirus type 1. Vaccine. 17:1999;933-943.
9. Baer G.M., Brooks R.C., Foggin C.M. Oral vaccination of dogs fed canine adenovirus in baits. Am. J. Vet. Res. 50:1989;836-837.
10. Summer J.W., Shaddock J.H., Wu G.J., Baer G.M. Oral vaccination of an attenuated strain of canine adenovirus (type 2) to raccoons, foxes, skunk and mongoose. Am. J. Vet. Res. 49:1988;169-171.
11. Appel M., Carmichael L.E., Robson D.S. Canine adenovirus type 2-induced immunity to two canine adenoviruses in pups with maternal antibody. Am. J. Vet. Res. 36:1975;1199-1202.
12. Perkus M.E., Kauffman E.B., Taylor J., Mercer S., Smith D., VanderHoeven J.et al. Methodology of using vaccinia virus to express foreign genes in tissue culture. J. Tissue Cult. Methods. 15:1983;72-81.
13. Robinson A.J., Younghusband H.B., Bellett A.J.D. A circular DNA-protein complex from adenoviruses. Virology. 56:1973;54-69.
14. Sambrook J, Russell DW. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1989.
15. Linne T. Differences in the E3 regions of the canine adenovirus type 1 and type 2. Virus Res. 23:1992;119-133.
16. Lafemina R.L., Pizzorno M.C., Mosca J.D., Hayward G.S. Expression of the acidic nuclear immediate-early protein (IE1) of human cytomegalovirus in stable cell lines and its preferential association with metaphase chromosomes. Virology. 172:1989;584-600.
17. Pardo M.C., Bauman J.E., Mackowiak M. Protection of dogs against canine distemper by vaccination with a canarypox virus recombinant expressing canine distemper virus fusion and hemagglutinin glycoproteins. Am. J. Vet. Res. 58:1997;833-836.
18. Pincus S., Mason P.W., Konishi E., Fonseca B.A., Shope R.E., Rice C.M.et al. Recombinant vaccinia virus producing the prM and E proteins of yellow fever virus protects mice from lethal yellow fever encephalitis. Virology. 187:1992;290-297.
19. Bass E.P., Gill M.A., Beckenhauer W.H. Evaluation of a canine adenovirus type 2 strain as a replacement for infectious canine hepatitis vaccine. J. Am. Vet. Med. Assoc. 177:1980;234-242.
20. Bett A.J., Prevec L., Graham F.L. Packaging capacity and stability of human adenovirus type 5 vectors. J. Virol. 67:1993;5911-5921.
21. Ghosh-Choudhury G., Haj-Ahmad Y., Graham F.L. Protein IX, a minor component of the human adenovirus capsid, is essential for the packaging of full length genomes. EMBO J. 6:1987;1733-1739.
22. Boshart M., Weber F., Jahn G., Dorsch-Hasler K., Fleckenstein B., Schaffner W. A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus. Cell. 4:1985;521-530.
23. Gorman C.M., Gies D., McCray G., Huang M. The human cytomegalovirus major immediate early promoter can be trans-activated by adenovirus early proteins. Virology. 171:1989;377-385.
24. Curtis R., Jemmett J.E., Furminger I.G. The pathogenicity of an attenuated strain of canine adenovirus type 2 (CAV2). Vet. Rec. 103:1978;380-381.
25. Lubeck M.D., Natuk R.J., Chengalvala M., Chanda P.K., Murthy K.K., Murthy S.et al. Immunogenicity of recombinant adenovirus-human immunodeficiency virus vaccines in chimpanzees following intranasal administration. AIDS Res. Hum. Retroviruses. 10:1994;1443-1449.
26. Wang Y., Xiang Z., Pasquini S., Ertl H.C. The use of an E1-deleted, replication-defective adenovirus recombinant expressing the rabies virus glycoprotein for early vaccination of mice against rabies virus. J. Virol. 71:1997;3677-3683.
27. Mittal S.K., Papp Z., Tikoo S.K., Baca-Estrada M.E., Yoo D., Benko M.et al. Induction of systemic and mucosal immune responses in cotton rats immunized with human adenovirus type 5 recombinants expressing the full and truncated forms of bovine herpesvirus type 1 glycoprotein gD. Virology. 222:1996;299-309.
28. Chengalvala M.V., Bhat B.M., Bhat R.A., Dheer S.K., Lubeck M.D., Purcell R.H.et al. Replication and immunogenicity of Ad7-, Ad4-, and Ad5-hepatitis B virus surface antigen recombinants, with or without a portion of E3 region, in chimpanzees. Vaccine. 15:1997;335-339.
29. Zakhartchouk A.N., Pyne C., Mutwiri G.K., Papp Z., Baca-Estrada M.E., Griebel P.et al. Mucosal immunization of calves with recombinant bovine adenovirus-3: induction of protective immunity to bovine herpesvirus-1. J. Gen. Virol. 80:1999;1263-1269.
30. Klonjkowski B., Gilardi-Hebenstreit P., Hadchouel J., Randrianarison V., Boutin S., Yeh P.et al. A recombinant E1-deleted canine adenoviral vector capable of transduction and expression of a transgene in human-derived cells and in vivo. Hum. Gene Ther. 8:1997;2103-2115.
31. Kremer E.J., Boutin S., Chillon M., Danos O. Canine adenovirus vectors: an alternative for adenovirus-mediated gene transfer. J. Virol. 74:2000;505-512.
32. Wold W.S., Gooding L.R. Region E3 of adenovirus: a cassette of genes involved in host immuno-surveillance and virus-cell interactions. Virology. 184:1991;1-8.
33. Randrianarison-Jewtoukoff V., Perricaudet M. Recombinant adenoviruses as vaccines. Biologicals. 23:1995;145-157.
34. Ginsberg H.S., Lundholm-Beauchamp U., Horswood R.L., Pernis B., Wold W.S., Chanock R.M.et al. Role of early region 3 (E3) in pathogenesis of adenovirus disease. Proc. Natl. Acad. Sci. U.S.A. 86:1989;3823-3827.
35. Babiuk L.A., Tikoo S.K. Adenoviruses as vectors for delivering vaccines to mucosal surfaces. J. Biotechnol. 83:2000;105-113.
36. Yang Y., Li Q., Ertl H.C., Wilson J.M. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J. Virol. 69:1995;2004-2015.